| Treatment cycles |
|
| Total |
550 |
| Median (Range) |
4 (1−29) |
| Response to decitabine |
|
| Complete remission (CR) |
11/85 (12.9%) |
| CR with incomplete blood count recovery (CRi) |
4/85 (4.7%) |
| Partial remission (PR) |
12/85 (14.1%) |
| Hematologic improvement (HI) without an objective response |
18/85 (21.2%) |
| Treatment failure |
58/85 (68.2%) |
| Clinical benefit rate (CR + CRi + PR + HI only) |
45/85 (52.9%) |
| Not evaluable |
11 (11.5%) |
| Hematologic improvement (HI) |
|
| HI, neutrophil |
29/78 (37.2%) |
| HI, erythrocyte |
32/78 (41.0%) |
| HI, platelet |
28/77 (36.4%) |
| HT, any |
45/90 (50.0%) |
| Death during induction therapy (during the first cycle of decitabine) |
12 (12.5%) |
| Causes of induction mortality |
|
| Infection |
9 (9.4%) |
| Rapidly progressive disease |
2 (2.1%) |
| Other than acute myeloid leukemia (AML) |
1 (1.0%) |
| Adverse events (AEs) ≥ grade 3 |
42 (43.8%) |
| Infection ≥ grade 3 |
36 (37.5%) |
| Bacteria ≥ grade 3 |
31 (32.3%) |
| Fungus ≥ grade 3 |
6 (6.3%) |
| Virus ≥ grade 3 |
1 (1.0%) |
| Pneumocystis ≥ grade 3 |
1 (1.0%) |
| Discontinuation of decitabine without progressive disease or treatment-related mortality |
25 (26.0%) |
| Causes of discontinuation |
|
| Deteriorated performance |
21 (21.8%) |
| Withdrawal of consent |
2 (2.1%) |
| Unknown |
2 (2.1%) |
